The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection
Open accessAbstract
Background & Aims The interferon-free regimen of simeprevir plus sofosbuvir was recommended by professional guidelines for certain patients with hepatitis C virus (HCV) genotype 1 infection based on the findings of a phase 2 trial. We aimed to evaluate the safety and efficacy of this regimen in clinical practice settings in North America. Methods We collected demographic, clinical, and virologic data, as well as reports of adverse outcomes, from sequential participants in HCV-TARGET—a prospective, observational cohort study of patients undergoing HCV treatment in routine clinical care settings. From January through October 2014, 836 patients with HCV genotype 1 infection began 12 weeks of treatment with simeprevir plus sofosbuvir (treatment duration of up to 16 weeks); 169 of these patients received ribavirin. Most patients were male (61%), Caucasian (76%), or black (13%); 59% had cirrhosis. Most had failed prior treatment with peginterferon and ribavirin without (46%) or with telaprevir or boceprevir (12%). The primary outcome was sustained virologic response (SVR), defined as level of HCV RNA below quantification at least 64 days after the end of treatment (beginning of week 12 after treatment—a 2 week window). Logistic regression models with inverse probability weights were constructed to adjust for baseline covariates and potential selection bias. Results The overall rate of SVR rate was 84% (675/802 patients, 95% CI: 81–87%). Model-adjusted estimates indicate patients with cirrhosis, prior decompensation, and previous protease inhibitor treatments were less likely to achieve an SVR. The addition of ribavirin had no detectable effects on SVR. The most common adverse events were fatigue, headache, nausea, rash, and insomnia. Serious adverse events and treatment discontinuation occurred in only 5% and 3% of participants, respectively. Conclusions In a large, prospective observational cohort study, a 12 week regimen of simeprevir plus sofosbuvir was associated with high rates of SVR and infrequent treatment discontinuation. ClinicalTrials.gov: NCT01474811
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Determination of reliability criteria for liver stiffness evaluation by transient elastography
Boursier, J., Zarski, J.-P., de Ledinghen, V., Rousselet, M.-C., Sturm, N., Lebail, B., Fouchard-Hubert, I., Gallois, Y., Oberti, F., Bertrais, S., et al. (2013) · Hepatology · doi:10.1002/hep.25993 · Cited by 662
Cited by
Reig, M., Mariño, Z., Perelló, C., Iñarrairaegui, M., Ribeiro, A., Lens, S., Díaz, A., Vilana, R., Darnell, A., Varela, M., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.008 · Cited by 1,018
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
Metadata
- Authors
- Sulkowski, M. S., Vargas, H. E., Di Bisceglie, A. M., Kuo, A., Reddy, K. R., Lim, J. K., Morelli, G., Darling, J. M., Feld, J. J., Brown, R. S., Frazier, L. M., Stewart, T. G., Fried, M. W., Nelson, D. R., Jacobson, I. M., Afdhal, N., Alam, I., Ben-Ari, Z., Bredfeldt, J., Brown, R. S., Chung, R. T., Darling, J., Harlan, W., Di Bisceglie, A. M., Dickson, R. C., Elbeshbeshy, H. A., Everson, G., Feld, J., Fenkel, J. M., Fried, M. W., Galati, J., Gordon, S. C., Hassan, M., Hawkins, T. N., Hinestrosa, F., Jacobson, I. M., Kerr, C. A., Kuo, A., Kwo, P. Y., Levitsky, J., Lim, J., Lok, A. S., Mailliard, M., Manns, M. P., Morelli, G., Muir, A. J., Nelson, D., O’Leary, J. G., Pearlman, B. L., Pockros, P., Ramani, A., Reau, N., Reddy, K. R., Schiff, E. R., Sherman, K. E., Shiffman, M. L., Smith, C., Spivey, J. R., Sterling, R. K., Sulkowski, M. S., Szabo, G., Terrault, N. A., Trautwein, C., Vargas, H. E., Watts, K., Williams, A., & Zeuzem, S.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 150
- Issue
- 2
- Pages
- 419-429
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2138619940
- Cited by
- 176
- References
- 2
- FWCI
- 21.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. https://app.cochat.ai/papers/10.1053/j.gastro.2015.10.013
- The paper
- Sulkowski, M. S., Vargas, H. E., Di Bisceglie, A. M., Kuo, A., Reddy, K. R., Lim, J. K., Morelli, G., Darling, J. M., Feld, J. J., Brown, R. S., Frazier, L. M., Stewart, T. G., Fried, M. W., Nelson, D. R., Jacobson, I. M., Afdhal, N., Alam, I., Ben-Ari, Z., Bredfeldt, J., . . . Zeuzem, S. (2016). Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. https://doi.org/10.1053/j.gastro.2015.10.013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.